Department of Medical Oncology, Barcelona Clinic Hospital, Translational Genomics and Targeted Therapies in Solid Tumours, IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain.
Department of Medical Oncology, Jerez de la Frontera University Hospital, Cádiz, Spain.
Clin Transl Oncol. 2024 Feb;26(2):352-362. doi: 10.1007/s12094-023-03262-x. Epub 2023 Jul 25.
The incidence and mortality of lung cancer in women are rising, with both increasing by 124% between 2003 and 2019. The main risk factor for lung cancer is tobacco use, but indoor radon gas exposure is one of the leading causes in nonsmokers. The most recent evidence demonstrates that multiple factors can make women more susceptible to harm from these risk factors or carcinogens. For this consensus statement, the Association for Lung Cancer Research in Women (ICAPEM) invited a group of lung cancer experts to perform a detailed gender-based analysis of lung cancer. Clinically, female patients have different lung cancer profiles, and most actionable driver alterations are more prevalent in women, particularly in never-smokers. Additionally, the impact of certain therapies seems to be different. In the future, it will be necessary to carry out specific studies to improve the understanding of the role of certain biomarkers and gender in the prognosis and evolution of lung cancer.
女性肺癌的发病率和死亡率正在上升，2003 年至 2019 年间，这两个数据分别上升了 124%。肺癌的主要风险因素是吸烟，但室内氡气暴露是不吸烟者的主要致病因素之一。最近的证据表明，多种因素可能使女性更容易受到这些风险因素或致癌物质的伤害。为了达成这一共识声明，妇女肺癌研究协会 (ICAPEM) 邀请了一组肺癌专家对肺癌进行详细的基于性别的分析。从临床角度来看，女性患者的肺癌特征不同，且大多数可操作的驱动基因改变在女性中更为普遍，尤其是在从不吸烟的女性中。此外，某些疗法的效果似乎也有所不同。未来，有必要开展具体的研究，以提高对某些生物标志物和性别在肺癌预后和演变中作用的理解。
